{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:26:27Z","timestamp":1793571987288,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the clinical role, durability, anatomical response, and safety for suprachoroidal triamcinolone acetonide (SCTA) (Xipere) in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were manually extracted from health records at a high-volume retina practice in Cleveland, Ohio. All patients with noninfectious inflammatory macular edema undergoing SCTA (\u22651 billing code) between October 25, 2021, and July 17, 2025, were included. Patients with known systemic autoimmune or infectious associations were excluded. Unique eyes were defined by MRN + laterality, with \u201cOU\u201d entries split into OD\/OS. Patient demographics, underlying diagnosis categorization, time between first and second injection (for eyes with \u22652 injections) were summarized. Pre- versus post-treatment central retinal thickness (CRT) and intraocular pressure (IOP) were compared via paired t-tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 177 patients (195 eyes) received 340 SCTA injections for macular edema associated with an underlying diagnosis of intermediate uveitis (10%), pseudophakic cystoid macular edema (31%), and posterior uveitis (59%). The time between first and second injection was approximately 5 months [SD \u00b1 72.5; median 144 (min 35, max 427)]. From baseline to follow-up, mean CRT decreased by 103 \u00b5m [95% CI: (\u2212122,\u221283.2),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001], while IOP increased minimally [mean difference 0.7 mmHg, 95% CI: (\u22120.02, 1.43),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.057]; and was medically managed when elevated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this real-world cohort, findings suggest that SCTA achieves robust anatomical improvement, a favorable IOP profile, and prolonged durability across patients with inflammation-related macular edema.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261461177","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:41:18Z","timestamp":1781329278000},"page":"653-657","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Anatomical Outcomes of Suprachoroidal Triamcinolone Acetonide Injections in a Large Retinal Practice over a 4-Year Period"],"prefix":"10.1177","volume":"42","author":[{"given":"Chase W.","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Nazareth Hospital, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey A.","family":"Scroggins","sequence":"additional","affiliation":[{"name":"University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Wuller","sequence":"additional","affiliation":[{"name":"Retina Associates of Cleveland, Inc., Beachwood, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella J.","family":"Hegarty","sequence":"additional","affiliation":[{"name":"Northeast Ohio Medical University, Rootstown, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Utrup","sequence":"additional","affiliation":[{"name":"University of Cincinnati, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camari D.","family":"Griffin","sequence":"additional","affiliation":[{"name":"Lincoln Memorial University-Debusk College of Osteopathic Medicine, Knoxville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Zaky","sequence":"additional","affiliation":[{"name":"Ohio University-Heritage College of Osteopathic Medicine, Athens, Ohio, United States of America."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"James","sequence":"additional","affiliation":[{"name":"Retina Associates of Cleveland, Inc., Beachwood, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison D.","family":"Sciulli","sequence":"additional","affiliation":[{"name":"Retina Associates of Cleveland, Inc., Beachwood, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-8496","authenticated-orcid":false,"given":"David G.","family":"Miller","sequence":"additional","affiliation":[{"name":"Retina Associates of Cleveland, Inc., Beachwood, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Coney","sequence":"additional","affiliation":[{"name":"Retina Associates of Cleveland, Inc., Beachwood, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2395289"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.11.050"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001508"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00603-x"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0090"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2262015"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2022.2114456"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701895"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.413"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-016-0052-8"},{"key":"e_1_3_3_12_1","unstructured":"11.RStudio Team. RStudio: Integrated development environment for R. 2025. Available from: https:\/\/posit.co\/"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01777-1"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16091241"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-02808-5"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004677"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-024-06969-4"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00230-7"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"19.CADTH. Dexamethasone intravitreal implant (Ozurdex): reimbursement recommendation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK601799\/","DOI":"10.51731\/cjht.2023.535"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003312"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02667-w"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/24741264241280597"},{"issue":"8","key":"e_1_3_3_24_1","first-page":"1139","article-title":"Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)","volume":"106","author":"Khurana RN","year":"2022","unstructured":"23.Khurana RN, , Merrill P, , Yeh S, et al. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol 2022;106(8):1139\u20131144.","journal-title":"Br J Ophthalmol"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261461177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261461177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261461177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T21:34:10Z","timestamp":1793568850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261461177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12,1]]}},"alternative-id":["10.1177\/10807683261461177"],"URL":"https:\/\/doi.org\/10.1177\/10807683261461177","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}